What's the problem? [Regulatives / Guidelines]

posted by kumarnaidu – Mumbai, India, 2017-07-11 16:43 (2452 d 01:43 ago) – Posting: # 17533
Views: 21,062

Hi all,
Recently we did pilot and pivotal (Partial reference replicate) studies for WHO and we got high variability (CV=32%). In the USFDA product specific guidance they have suggested 2x2 crossover design for this drug. Based on our prior experience can we perform reference replicate study or need to go as per guidance?:confused:

Kumar Naidu

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,638 registered users;
93 visitors (0 registered, 93 guests [including 9 identified bots]).
Forum time: 17:27 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5